Background Biologics are used for the treatment of rheumatoid arthritis and many other
conditions. While the efficacy of biologics has been established, there is uncertainty regarding …

Background Serious infections are a major concern for patients considering treatments for
rheumatoid arthritis. Evidence is inconsistent as to whether biological drugs are associated …

Background The biologic disease‐modifying anti‐rheumatic drugs (DMARDs) are very
effective in treating rheumatoid arthritis (RA), however there is a lack of head‐to‐head …

Background Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used
as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as …

Background TNF (tumor necrosis factor)‐alpha inhibitors block a key protein in the
inflammatory chain reaction responsible for joint inflammation, pain, and damage in ankylosing …

… van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy
in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic …

Objective. To perform a systematic review of the benefits and harms of folic acid and folinic
acid in reducing the mucosal, gastrointestinal, hepatic, and hematologic side effects of …

Background Enhancing health equity is endorsed in the Sustainable Development Goals.
The failure of systematic reviews to consider potential differences in effects across equity …

Background Raynaud's phenomenon is a vasospastic disease characterized by digital
pallor, cyanosis, and extremity pain. Primary Raynaud's phenomenon is not associated with …

… (long term studies excluded, data cut up, discrepancies with review by Hall et al24), political
controversy related to a replication of primary study by Miguel et al (impact of errors)25 26 …